{"disease":{"id":"colorectal-cancer-in-combination-with-chemotherapy","name":"colorectal cancer in combination with chemotherapy"},"drugs":{"marketed":[{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed oxaliplatin-based chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}